Avalyn Pharma (NASDAQ:AVLN – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($21.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($16.38) by ($5.45), Zacks reports.
Avalyn Pharma Stock Performance
Shares of NASDAQ AVLN opened at $25.72 on Wednesday. Avalyn Pharma has a 12-month low of $25.05 and a 12-month high of $32.22.
Wall Street Analysts Forecast Growth
Several analysts have recently commented on AVLN shares. Wall Street Zen raised shares of Avalyn Pharma to a “hold” rating in a research report on Saturday, May 9th. Jefferies Financial Group started coverage on shares of Avalyn Pharma in a report on Monday, May 25th. They issued a “buy” rating and a $52.00 price objective on the stock. Guggenheim initiated coverage on shares of Avalyn Pharma in a report on Monday, May 25th. They issued a “buy” rating and a $80.00 target price for the company. Zacks Research raised Avalyn Pharma to a “hold” rating in a research note on Wednesday, May 27th. Finally, Evercore began coverage on shares of Avalyn Pharma in a research note on Tuesday, May 26th. They set an “outperform” rating and a $51.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $59.00.
Insider Activity
In related news, Director Jill Carroll purchased 277,778 shares of Avalyn Pharma stock in a transaction on Friday, May 1st. The shares were bought at an average price of $18.00 per share, with a total value of $5,000,004.00. Following the transaction, the director directly owned 2,186,562 shares of the company’s stock, valued at approximately $39,358,116. This trade represents a 14.55% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Sr One Capital Management, Llc purchased 555,555 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The stock was purchased at an average price of $18.00 per share, with a total value of $9,999,990.00. Following the purchase, the insider directly owned 2,186,562 shares of the company’s stock, valued at $39,358,116. The trade was a 34.06% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.
Avalyn Pharma Company Profile
We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.
Read More
- Five stocks we like better than Avalyn Pharma
- MongoDB Is the Latest SaaS Apocalypse Victim to Say “Not Today”
- Urban Outfitters Stock Stalls Despite Another Strong Quarter
- Berkshire Builds a Moat Around Homebuilders
- Tomato Prices Are Spiking, and These 2 Food Stocks Could Feel the Squeeze
Receive News & Ratings for Avalyn Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalyn Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
